Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Emerging Sponsors” Pose Regulatory, Public Relations Challenges For Drug Review Process, FDA’s Jenkins Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Office of New Drugs director says the agency is seeing more small, inexperienced companies traveling the drug development and approval pathway on their own. However, these firms need more advice from the agency and are all too eager to publicly share their one-sided view about these regulatory interactions.

Advertisement

Related Content

Gottlieb Q&A: Confirmation Is Nearing, Will Complete Response Letters Finally Get Released?
FDA Talking To Industry About Releasing “Complete Response” Letters
FDA Talking To Industry About Releasing “Complete Response” Letters
Late-Cycle Approval Predictions Not A Good Idea, FDA Says
Chelsea Took Proactive PR Approach For Northera Panel, But Will It Help Or Hurt?
NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
Emerging Sponsors And FDA: Will Better Communication Under PDUFA V Ease Inherent Tensions?
Oncology Price Scale Tips Higher: Seattle Genetics Adcetris To Cost Over $100K
PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel